Kristin Brooks, Contract Pharma05.18.20
While the pharmaceutical industry is less susceptible to market dynamics during a downturn as compared to other industries, this unpredictable environment amid the COVID-19 pandemic has pharma rethinking their portfolios and pipeline assets, supply chains, API sourcing, and manufacturing.
Arda Ural, Ph.D., a Principal and the Americas Industry Markets Leader, Health Sciences and Wellness at Ernst & Young LLP, provides insights on market dynamics, enduring therapeutic areas, near term M&A for pharma/biopharma, and how industry can use this time for transformation in commercial, supply chain and product development. –KB
Contract Pharma: How are pharma/biopharma companies a
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
